NCT04613297View on ClinicalTrials.gov

HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment

NACompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

October 19, 2020

Primary Completion Date

July 19, 2022

Study Completion Date

July 19, 2022

Conditions
Covid19
Interventions
OTHER

Baseline and during hospitalization blood samples

"Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed :~* at day 3~* day 5 and~* In case of aggravation~* At the discharge from hospital"

OTHER

Baseline blood sample

Blood sample will be performed at the inclusion visit only

Trial Locations (1)

92151

Foch hospital, Suresnes

All Listed Sponsors
lead

Hopital Foch

OTHER

NCT04613297 - HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment | Biotech Hunter | Biotech Hunter